Endo Pharmaceutical Holdings ENDP
-
Buckingham says Watson Pharmaceuticals ([[WPI]] -1.3%) remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo ([[ ENDP ]] ...
… remains a Top Pick , given its attractive growth profile, Actavis acquisition benefits and continued settlement discussions with Endo ( ENDP -0.8% ). The firm reiterates its Buy rating with a $100 price target. Post your comment!
-
New Morningstar Analyst Report - Watson Pharmaceuticals Inc.
… success. Such hard-to-manufacture products, including Watson's near-term opportunity with a generic version of Endo's ENDP Lidoderm, help sustain above-average growth and profitability when compared with conventional small molecule drugs. Furthermore …
-
Can Teva Win With The Big Pharma Playbook?
… and generic companies like Teva are in branded drugs. And just for good measure, a few outliers like Endo Pharmaceuticals ( ENDP ) add devices to the mix, while others like Abbott ( ABT ) and Covidien ( COV ) look to split and spin-off their drug businesses …
-
Endo Pharmaceuticals Holdings' CEO Discusses Q1 2012 Results - Earnings Call Transcript
Endo Pharmaceuticals Holdings Inc. ( ENDP ) Q1 2012 Earnings Call May 1, 2012 9:00 AM ET Executives Blaine Davis – Head, IR David Holveck – President and CEO Julie McHugh …
-
Near-Term Supply Issues and Generic Threats Weigh on Endo in 1Q
Endo Pharmaceuticals ENDP reported stagnant first-quarter results, which matched our expectations given previously announced temporary supply issues …
-
Endo Pharmaceuticals ( ENDP ): Q1 EPS of $0.87 beats by $0.01. Revenue of $691M (+23.3% Y/Y) misses by $9M. (PR)
Endo Pharmaceuticals ( ENDP ): Q1 EPS of $0.87 beats by $0.01 . Revenue of $691M (+23.3% Y/Y) misses by $9M . ( PR ) Post your comment!
-
Notable earnings before Tuesday’s open: [[ACI]], [[ADM]], [[ADP]], [[AGCO]], [[AMG]], [[ARW]], [[AVP]], [[BDX]], [[BIIB]], [[BP]], [[CCJ]], [[CIE]], [[CMI]], [[DPZ]], [[ECL]], [[EMR]], [[ ENDP ]], ...
… earnings before Tuesday’s open: ACI , ADM , ADP , AGCO , AMG , ARW , AVP , BDX , BIIB , BP , CCJ , CIE , CMI , DPZ , ECL , EMR , ENDP , FE , FWLT , HCP , HRS , HSP , HUN , LM , MLM , MMC , NI , PFE , PLD , SIRI , TLM , TRI , TRW , VLO , VPHM , WEC …
-
Watson Pharmaceuticals: Dealing Its Way To $100?
By Daniel Shvartsman : Jim Cramer often talks about investing based on certain themes. Obviously, he didn't come up with the idea of arranging investments under larger headings, but he is among the more vocal on the topic (along with many others). Some of his recent themes include "big data," the
-
Pharma Spin-Off Should Unlock Value of Covidien's Well-Positioned Device Business
… s pharma unit isn't facing major business disruptions like some of its peers, such as Lidoderm's patent loss for Endo ENDP , Cardiolite's patent loss for the former Bristol BMY imaging business, loss of Provigil for Cephalon (now part of Teva TEVA …
-
BioDelivery Sciences International: Strong Upside Potential
By Scott Matusow : In this article, I will be featuring an interesting little bio-pharma that a few investors brought to my attention over the past few weeks. This one might be a long term buy and hold, albeit risky for the long term, as most of these lower priced bio-pharmas certainly are. I ...